Trial reportDepression and anxiety2025
Concentrated ERP for Patients With Difficult-to-Treat OCD: Insight as a Predictor of Acute and Long-Term Outcomes.
Trial report in Depression and anxiety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Concentrated ERP for Patients With Difficult-to-Treat OCD: Insight as a Predictor of Acute and Long-Term Outcomes.Depression and anxiety · 2025Trial
- Making Sense of Non-Response: What Patients Teach Us About Concentrated Exposure Therapy for Obsessive Compulsive Disorder.Journal of clinical medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive-behavioral therapy (CBT) with exposure and response prevention (ERP) is a recommended treatment for obsessive-compulsive disorder (OCD), although many patients who undergo this regimen do not achieve satisfactory symptom relief, and maintaining long-term remission is challenging. Concentrated exposure therapy (cET) has emerged as a potential treatment for treatment-resistant OCD. However, the role of insight as a predictor of treatment outcomes in this context remains underexplored. Methods: We conducted a secondary analysis of a randomized controlled trial (RCT) including 163 adults diagnosed with treatment-resistant OCD. This study used linear regression models to evaluate whether pre-treatment levels of insight and changes in insight-measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) insight item-were associated with outcomes after 4 days of cET and whether insight levels changed post-treatment. Results: Baseline insight did not predict OCD severity at post-treatment or 3-month follow-up but was associated with greater OCD severity at the 12-month follow-up. Insight scores improved significantly from pre- to post-treatment but worsened during the follow-up period. Notably, a change in insight during cET was a significant predictor of OCD symptom severity at all follow-up intervals. Conclusions: Baseline insight was not a strong predictor of short-term treatment outcomes following cET but was related to long-term OCD severity. Improvements in insight during cET were associated with achieving and maintaining reduced symptoms over time. These results suggest that improvements in OCD and enhanced insight are associated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.